Does Dexamethasone Administration Improve Recovery In Patients Undergoing Minimally Invasive Sacrocolpopexy?
- Conditions
- Quality of LifePelvic Organ ProlapseProlapses, Vaginal Vault
- Interventions
- Drug: Normal salineDrug: Dexamethasone
- Registration Number
- NCT03094442
- Lead Sponsor
- The Cleveland Clinic
- Brief Summary
The primary aim is to evaluate whether standard administration of Dexamethasone at the time of general anesthesia induction at the time of minimally invasive sacrocolpopexy (MISC) would result in improved quality of recovery (QoR).
- Detailed Description
There has been a public outcry regarding the continuing rise of health care expenditures. In 1997, the estimated costs of surgery for pelvic organ prolapse (POP) were $ 100.1 million. It is important to identify interventions that would improve the QoR in this patient population and to speed-up postoperative recovery. As most of these surgeries are performed in an outpatient manner as a 23 hour observation, improved recovery may also speed discharge and free-up valuable hospital resources.
Patients will receive either Dexamethasone or placebo ( normal saline) at the time of induction of general anesthesia. QoR questionnaires, Pain scale and postoperative nausea and vomiting scale (PONV).
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- Female
- Target Recruitment
- Not specified
- Women over the age of 18
- Women scheduled for minimally invasive sacrocolpopexy with or without concomitant anti-incontinence procedure and with or without concomitant hysterectomy
- American Society of Anesthesiologists (ASA) class 1-2
- Daily use of steroids, antiemetics in the month prior to surgery
- Chronic pain requiring daily opioid treatment
- History of allergy/intolerance to Dexamethasone
- ASA class 3
- Numerical Pain score (NPS) of more than 4 at baseline
- Renal/Liver disease
- Diabetes mellitus
- Pregnancy
- Inability to answer questionnaires
- Any systemic infections
- Immuno compromised status
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Saline Normal saline Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy. Dexamethasone Dexamethasone Dexamethasone is a potent corticosteroid that has been widely used for chemotherapy induced nausea and vomiting. The mechanism of action is not completely understood. It has been proposed that a single dose may hinder the production and release of anti-inflammatory mediators. Dexamethasone also has a central antiemetic effect by inhibition of prostaglandin and/or release of endogenous opioids. A recent metanalysis concluded that Dexamethasone administration at induction is safe. We will be using a 8mg dose of Dexamethasone, that is equivalent to 2ml of injectable drug.
- Primary Outcome Measures
Name Time Method Quality of recovery 40 (QoR-40) baseline, 24 hours, 6 weeks Quality of Recovery 40 will be recorded at baseline, 24 hours and 6 weeks. The change in the mean scores will be computed for each group. The primary endpoint of change in QoR from baseline will be analyzed through t- test.
- Secondary Outcome Measures
Name Time Method Numerical Pain Scale baseline, 24 hours, 6 weeks Pain at baseline, 24 hours and 6 weeks will be recorded.
Postoperative Nausea Vomiting Scale 6 weeks Immediate nausea and vomiting 24 hours after surgery. Use of rescue antiemetics will be recorded
Trial Locations
- Locations (1)
Cleveland Clinic Florida
🇺🇸Weston, Florida, United States